Evidence map›Paper›PMID 31662531›Full record

ArticleIn vivo (Athens, Greece)

T-Lymphocyte Activation Is Correlated With the Presence of Anti-EBV in Patients With Laryngeal Squamous Cell Carcinoma.

Janusz Klatka, Anna Hymos, Anna Szkatuła-Łupina, Ewelina Grywalska, Barbara Klatka, Michał Terpiłowski, Andrzej Stepulak

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Antibodies as biomarkers for cancer risk: a systematic review.Clinical and experimental immunology · 2022
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Janusz KlatkaDepartment of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Anna HymosDepartment of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Anna Szkatuła-ŁupinaDepartment of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.
Barbara KlatkaDepartment of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Michał TerpiłowskiDepartment of Otolaryngology and Laryngeal Oncology, Medical University of Lublin, Lublin, Poland.
Andrzej StepulakDepartment of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland andrzej.stepulak@umlub.pl.
Medical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimChronic viral infection is an important risk factor in the development of cancer. Failure of immune response to clear the oncogenic infection can facilitate cancer progression. The aim of the present study was to analyze early and late activation of T-lymphocytes related to Epstein-Barr virus (EBV) infection by the expression of markers of activation (CD69, CD25) on the surface of T-lymphocytes (CD3 MATERIALS AND

methodsThirty-three patients with laryngeal squamous cell carcinoma (LC) and 20 volunteers without cancer (control group) were enrolled in the study. Peripheral blood samples were collected from every individual. The markers of activation of T-lymphocytes were determined by flow cytometry, whereas commercial immunoenzymatic assay kits were used for detection of anti-viral capsid antigen (VCA) IgM, anti-VCA IgG, and anti-EBNA1 IgG.

resultsIncreased early activation of CD8

conclusionThe dysfunction of immune response in larynx cancer patients could be associated with EBV infection.

Indexed as

Antibodies, ViralAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, ViralBiomarkers, TumorCapsid ProteinsCarcinoma, Squamous CellCD69 AntigensEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensFemaleHerpesvirus 4, HumanHumansImmunoglobulin GImmunoglobulin MInterleukin-2 Receptor alpha SubunitAntibodies, ViralAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, ViralBiomarkers, TumorCapsid ProteinsCD69 AntigensEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensImmunoglobulin GImmunoglobulin MInterleukin-2 Receptor alpha SubunitLectins, C-Typeantibodies to EBVLaryngeal squamous cell carcinomaT-lymphocyte activation

Identifiers

PMID31662531
PMCPMC6899120
OpenAlexW2985719388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.